Rosetta Puts Blood-Based Cancer Screen on Back Burner to Refocus on miRNA Diagnostics | GenomeWeb

By Doug Macron

Rosetta Genomics this month announced that it has scaled back its work on a serum-based colon cancer-screening assay based on microRNA biomarkers, less than a year after the company said that commercialization of the test, dubbed miRscreen Colon, had become its top priority.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: effect of variants linked to body shape differs by age and sex, transcriptome differences in bats with and without white-nose syndrome, and more.

A researcher argues that big prizes like the Nobel or Lasker awards send the wrong message about research.

Maria Freire, the president of the Foundation for the National Institutes of Health, discusses recent genomics-fueled advances with The Open Mind's Alexander Heffner.

Three researchers win the Nobel Prize for their efforts to develop treatments for parasitic diseases.